Abstract
Pancreatic ductal adenocarcinoma (PDAC) has a remarkable trend to metastasize early. Accordingly, there is a strong rational to investigate neoadjuvant chemotherapy in patients with resectable disease. We conducted a multicenter randomized phase II trial (PACT-15; NCT01150630) to assess the role of combination chemotherapy in perioperative setting.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
